Introduction {#H1-1-ZOI190099}
============

Epilepsies are among the most common neurologic disorders, with an estimated prevalence of 6 in 1000 people worldwide.^[@zoi190099r1]^ Epilepsies encompass a heterogeneous group of clinical entities with diverse causes and outcomes. Although up to a third of epilepsy cases are due to acquired insults, such as birth trauma, brain injury, or a tumor, the remainder are attributable to genetic factors and include epilepsies with monogenic and complex inheritance.^[@zoi190099r2],[@zoi190099r3]^

Monogenic forms of seizure disorders tend to manifest earlier in life. Their clinical spectrum is broad, ranging from benign, self-limited epilepsies; epilepsies due to inborn errors of metabolism; epilepsies with other neurodevelopmental issues, such as autism or intellectual disability; and early-onset, severe epileptic encephalopathies.^[@zoi190099r4],[@zoi190099r5],[@zoi190099r6]^ Early establishment of a specific diagnosis is necessary for providing an accurate prognosis and recurrence risk as well as optimizing management and treatment options. However, high genetic heterogeneity and phenotypic pleiotropy make it challenging to clinically differentiate between genetically distinct epilepsies. Pathogenic variants in numerous genes may lead to indistinguishable epilepsies, and variation in the same gene can result in epilepsies with differing presentation, both in severity and comorbidity manifestation.^[@zoi190099r2],[@zoi190099r4],[@zoi190099r6],[@zoi190099r7],[@zoi190099r8]^ Therefore, genetic testing often serves as a useful tool in finding a definitive cause and concluding the diagnostic process.

Pathogenic variants in the epilepsies can be diverse, ranging from large copy number variants (CNVs) to simple DNA sequence variants. Over the past decade, the number of genes implicated in epilepsy and the repertoire of genetic tests offered have grown significantly.^[@zoi190099r9],[@zoi190099r10]^ In addition to traditional cytogenetic and microarray-based tests, comprehensive next-generation sequencing (NGS) panels, exome, and genome NGS tests are available for genetic epilepsy testing.^[@zoi190099r6],[@zoi190099r11]^ Each of those tests comes with its own advantages and limitations in terms of detectable genetic variant type, diagnostic yield, costs, and turnaround time. Although clinicians are challenged with navigating complex clinical algorithms for choosing the best genetic workup for a specific patient and with test result interpretation,^[@zoi190099r6],[@zoi190099r10]^ clinical laboratories are urged to devise comprehensive testing options, keep testing costs low and turnaround times short, and find solutions for maximizing diagnostic yield while staying abreast of the pace of gene discovery.

To address these diverse clinical and economic demands, we have developed an exome sequencing (ES)-based test for the pediatric epilepsy diagnosis focusing on an initial analysis of 100 epilepsy genes. The ES-based strategy enables easy reflex to analysis of the full exome for cases with a negative panel outcome and offers flexibility in modifying the panel's gene content in response to new gene discoveries or clinical demands. Herein, we report on evaluation of the clinical test usefulness for a cohort of 151 consecutive patients with childhood-onset epilepsy and discuss strategies for improving diagnostic yield.

Methods {#H1-2-ZOI190099}
=======

Patients {#H2-1-ZOI190099}
--------

This study cohort included 151 consecutive, unrelated patients referred by neurologists from a single academic tertiary medical center for genetic testing of childhood epilepsy between September 26, 2016, and January 8, 2018. All but 1 patient were tested using a comprehensive, exome-based epilepsy panel. The main indication for testing was epilepsy of unknown source in patients in whom epilepsy was the primary disease phenotype. The clinical patient data presented in this study are based on medical records available at the time of the test order. All patient samples were deidentified for this report. The study was reviewed by the institutional review board of Children's Hospital of Philadelphia and was determined to meet exemption criteria with waiver of informed consent. This study followed the [reporting guideline](http://www.ajo.com/article/S0002-9394(10)00690-2/fulltext) for case series.

Gene Curation {#H2-2-ZOI190099}
-------------

The panel included 100 genes selected for targeted testing based on literature reports implicating variants in these genes with nonsyndromic epilepsy or apparently nonsyndromic, when epilepsy was the first presenting or most prominent feature. The strength of evidence for each gene's association with disease was at least moderate based on an internal review using the Clinical Genome Consortium gene validity criteria.^[@zoi190099r12],[@zoi190099r13]^ Recently discovered genes with limited evidence were also included in anticipation of additional evidence supporting their potential association with epilepsy.

Comprehensive Exome-Based Sequencing Panel {#H2-3-ZOI190099}
------------------------------------------

Genomic DNA was obtained from peripheral blood or other patient tissues following standard DNA extraction protocols and was prepared for ES using previously described procedures.^[@zoi190099r14]^ An in-house bioinformatics pipeline^[@zoi190099r15]^ was used for NGS data analysis, including variant filtration and annotation. Only variants in the epilepsy panel regions of interest were retained (eMethods 1 in the [Supplement](#note-ZOI190099-1-s){ref-type="supplementary-material"}). The filtration process captured known pathogenic variants, as well as rare variants with a potential association with protein function or RNA splicing. Rare variants included (1) variants with minor allele frequency less than 1% if previously reported in the Human Gene Mutation Database, (2) variants with minor allele frequency less than 0.1% in genes associated with a dominant forms of epilepsy, and (3) variants with minor allele frequency less than 0.57% in genes associated with recessive forms of epilepsy. The minor allele frequency cutoffs were calculated as previously described.^[@zoi190099r15]^ Variants were then filtered based on their frequencies in the Exome Aggregation Consortium database.

Exon-level CNVs were called from ES coverage data by an in-house pipeline, using ExomeDepth.^[@zoi190099r16]^ Coverage assessment and criteria for ad hoc Sanger sequencing fill-in have been described previously.^[@zoi190099r15]^ More information about the ES-based and rapid STAT Epilepsy Panel can be found in eMethods 1 and eMethods 2 in the [Supplement](#note-ZOI190099-1-s){ref-type="supplementary-material"}.

Genes included in the analysis of the ES epilepsy panel were *ALDH7A1*, *ALG13*, *ARHGEF9*, *ARX*, *ASAH1*, *ATP1A2*, *ATP1A3*, *CACNA1A*, *CACNA1D*, *CASK*, *CDKL5*, *CERS1*, *CHD2*, *CHRNA2*, *CHRNA4*, *CHRNB2*, *CLN3*, *CLN5*, *CLN6*, *CLN8*, *CNKSR2*, *CSTB*, *CTSD*, *DEPDC5*, *DNM1*, *DYNC1H1*, *EEF1A2*, *EFHC1*, *EPM2A*, *FOLR1*, *FOXG1*, *GABRA1*, *GABRB3*, *GABRG2*, *GNAO1*, *GOSR2*, *GRIN1*, *GRIN2A*, *GRIN2B*, *HCN1*, *HDAC4*, *HNRNPU*, *IQSEC2*, *KCNA1*, *KCNA2*, *KCNB1*, *KCNC1*, *KCNJ10*, *KCNQ2*, *KCNQ3*, *KCNT1*, *KCTD7*, *LGI1*, *MECP2*, *MEF2C*, *MFSD8*, *NHLRC1*, *PCDH19*, *PIGA*, *PIGO*, *PIGT*, *PLCB1*, *PNKP*, *PNPO*, *POLG*, *PPT1*, *PRICKLE1*, *PRRT2*, *PURA*, *QARS*, *RELN*, *RYR3*, *SCARB2*, *SCN1A*, *SCN1B*, *SCN2A*, *SCN8A*, *SIK1*, *SLC12A5*, *SLC13A5*, *SLC25A22*, *SLC2A1*, *SLC35A2*, *SLC6A1*, *SLC6A8*, *SPTAN1*, *ST3GAL3*, *STX1B*, *STXBP1*, *SYN1*, *SYNGAP1*, *SZT2*, *TBC1D24*, *TPP1*, *TSC1*, *TSC2*, *WDR45*, *WWOX*, *UBE3A*, and *ZEB2*. Gene identification numbers are available in the eTable in the [Supplement](#note-ZOI190099-1-s){ref-type="supplementary-material"}.

Variant Classification and Determination of Diagnostic Outcome {#H2-4-ZOI190099}
--------------------------------------------------------------

Rare sequence variants or CNVs were classified in accordance with the framework of the standards and guidelines published by the American College of Medical Genetics and Genomics.^[@zoi190099r17]^ A result was considered diagnostic if a clinically significant variant (pathogenic or likely pathogenic) was identified in an autosomal-dominant gene or if there were 2 clinically significant variants identified in *trans* for autosomal-recessive genes. A negative result was concluded if no reportable variants were identified. All other results were considered inconclusive. Parental testing was offered free-of-charge for panel-inconclusive cases that had reportable variants in autosomal-dominant genes or 2 variants in autosomal-recessive genes. A subset of inconclusive reports was considered likely diagnostic and included cases that had 1 or more heterozygous variant in autosomal-dominant gene or 2 heterozygous variants in recessive genes that were rare or absent from large population studies, such as gnomAD,^[@zoi190099r18]^ and that affected critical protein regions, such as ion channel domains, or those that had de novo variants in genes with limited clinical validity.

Statistical Analysis {#H2-5-ZOI190099}
--------------------

Categorical variables were summarized using proportions with 95% CIs provided where applicable. Median and interquartile range (IQR) were provided for continuous variables. A χ^2^ test of independence was performed using online tools^[@zoi190099r19]^ to evaluate the significance of diagnostic yield across different patient groupings. For age at seizure onset group comparison, the early childhood and older groups were combined into 1 group; for seizure type group comparison, patients with febrile and unknown type of seizures were excluded; for brain magnetic resonance imaging findings and family history group comparisons, patients with undetermined magnetic resonance imaging findings or unknown family history were excluded. Williams correction for small sample size was applied where applicable. *P* \< .01 was considered statistically significant. A tool available online was used for data analysis.^[@zoi190099r19]^

Results {#H1-3-ZOI190099}
=======

Cohort Description {#H2-6-ZOI190099}
------------------

The patient cohort included 151 children and young adults with epilepsy with relatively even sex distribution (67 \[44.4%\] female and 84 \[55.6%\] male). Age at testing ranged between 0 and 22 years, with median age at testing of 4.2 years (IQR, 1.4-8.7 years) ([Figure 1](#zoi190099f1){ref-type="fig"}A). At the time of requisition, 69 patients (45.7%) were noted to manifest additional neurodevelopmental features, including developmental delay, learning disability, speech delay, and/or behavioral issues (referred to as seizure plus) ([Table 1](#zoi190099t1){ref-type="table"}). Median age at seizure onset was 1.83 years (IQR, 0.5-3.75 years). Focal seizures were reported in 61 children (40.4%), followed by 49 children (32.5%) with generalized seizures and 26 children (17.2%) with mixed-type seizures. Magnetic resonance imaging findings were noted in 58 patients (38.4%); however, the findings were considered noncontributory by the patients' neurologists and included reports such as atrophy, nonspecific white matter changes, or decreased myelination.

![Cohort Demographics and Genetic Testing Data\
A, Age at testing and sex distribution. B, Additional genetic testing received by the patients. CHOP Urgent includes Rapid Epilepsy Sequence and Deletion/Duplication (STAT) Panel. Epilepsy-related genes include *SCN1A*, *SCN1B*, *GABRG2*, *ARX*, *CNTNAP2*, *TSC1/2*, *CHRNA4*, *CHRNB2*, and mitochondrial DNA. Other syndromes include Coffin-Lowry, X-linked mental retardation, and microcephaly. Rett/AS/PW indicates testing for Rett, Angelman, and Prader-Willi syndromes, and includes *MECP2* sequencing and deletion/duplication testing, CDKL5 sequencing, and atypical Rett syndrome testing. Prior exome sequencing arrays were performed at other diagnostic laboratories. Non-epilepsy testing includes genetic tests for thrombosis, ketotic hypoglycemia, ichthyosis, connexin 26, and tumor. CMA indicates chromosomal microarray analysis.](jamanetwopen-2-e192129-g001){#zoi190099f1}

###### Testing Outcome Stratified by Cohort Clinical Characteristics

  Cohort                                                    Patients, No. (% Category)   Category Total (% All Cohort)   *P* Value               
  --------------------------------------------------------- ---------------------------- ------------------------------- ----------- ----------- --------------------------------------------------
  Age at seizure onset                                                                                                                           
  Neonatal (0-1 mo)                                         1 (12.5)                     6 (75.0)                        1 (12.5)    8 (5.3)     \<.001[^a^](#zoi190099t1n1){ref-type="table-fn"}
  Infancy (1 mo-1 y)                                        17 (38.6)                    16 (36.4)                       11 (25.0)   44 (29.1)   
  Toddler (1-3 y)                                           8 (16.0)                     28 (56.0)                       14 (28.0)   50 (33.1)   
  Early childhood (3-5 y)                                   0                            12 (50.0)                       12 (50.0)   24 (15.9)   
  Middle childhood (6-11 y)                                 1 (5.3)                      11 (57.9)                       7 (36.8)    19 (12.6)   
  Adolescent (12-18 y)                                      0                            4 (66.7)                        2 (33.3)    6 (4.0)     
  Phenotype                                                                                                                                      
  Seizure only                                              12 (14.6)                    43 (52.4)                       27 (32.9)   82 (54.3)   .52
  Seizure plus[^b^](#zoi190099t1n2){ref-type="table-fn"}    15 (21.7)                    34 (49.3)                       20 (29.0)   69 (45.7)   
  Seizure type                                                                                                                                   
  Focal                                                     12 (19.7)                    30 (49.2)                       19 (31.1)   61 (40.4)   .25
  Generalized                                               6 (12.2)                     27 (55.1)                       16 (32.7)   49 (32.5)   
  Mixed                                                     9 (35)                       10 (38)                         7 (27)      26 (17.2)   
  Febrile                                                   0                            1 (100)                         0           1 (0.06)    
  Unknown                                                   0                            9 (64.3)                        5 (35.7)    14 (9.3)    
  Brain MRI                                                                                                                                      
  With findings[^c^](#zoi190099t1n3){ref-type="table-fn"}   15 (25.9)                    24 (41.4)                       19 (32.8)   58 (38.4)   .19
  No findings                                               12 (15.4)                    43 (55.1)                       23 (29.5)   78 (51.7)   
  Not determined                                            0                            10 (66.7)                       5 (33.3)    15 (9.9)    
  Family history                                                                                                                                 
  Positive                                                  7 (14.0)                     30 (60.0)                       13 (26.0)   50 (33.1)   .19
  Negative                                                  20 (22.7)                    39 (44.3)                       29 (33.0)   88 (58.3)   
  Unknown                                                   0                            8 (61.5)                        5 (38.5)    13 (8.6)    

Abbreviation: MRI, magnetic resonance imaging.

Williams correction applied.

Includes patients presenting with developmental and behavioral phenotypes, such as developmental delay, developmental regression, speech or language delay, attention-deficit/hyperactivity disorder or autism.

Includes any abnormality identified by MRI.

All cases but 1 were tested by the exome-based epilepsy panel. One patient, originally referred to the exome panel, was instead expedited, per clinician's request, for sequencing using a smaller, medically actionable rapid epilepsy panel (eMethods 2 in the [Supplement](#note-ZOI190099-1-s){ref-type="supplementary-material"}).

Additional Genetic Testing {#H2-7-ZOI190099}
--------------------------

Seventy-eight of the 151 patients (51.7%) had at least 1 additional genetic test done besides the epilepsy panel, for a total of 132 additional tests. Sixty-two patients (41.1%) had chromosomal microarray analysis (CMA), which was ordered at the clinician's discretion mainly for patients with the seizure plus phenotype ([Table 1](#zoi190099t1){ref-type="table"}). Forty-three patients (28.5%) had the CMA test performed concurrently with the panel and 19 patients (12.6%) had it performed before the epilepsy panel test.

Prior karyotype testing was performed on 17 patients (11.3%). Fifteen patients (9.9%) underwent ES: 3 in another laboratory before referral and 12 who were reflexed to ES after a nondiagnostic panel result. Additional genetic testing included analysis for single epilepsy genes (11 \[7.3%\]); other epilepsy panels (3 \[2.0%\]); fragile X (6 \[4.0%\]); Rett, Angelman, or Prader-Willi syndromes (8 \[5.3%\]); other neurologic syndromes (3 \[2.0%\]); or non--epilepsy-related conditions (6 \[4.0%\]) ([Figure 1](#zoi190099f1){ref-type="fig"}B).

Genetic testing done before or concurrently with the panel yielded significant findings in 5 patients. Three patients had trisomies identified by karyotype (1 had Klinefelter syndrome \[XXY\] and 2 had trisomy 21) that were not considered explanatory for their seizures and, therefore, were referred for epilepsy panel testing. The panel testing revealed a heterozygous *PCDH19* pathogenic variant in the patient with Klinefelter syndrome (patient 5) ([Table 2](#zoi190099t2){ref-type="table"}), explaining his epilepsy.^[@zoi190099r20]^ The other 2 patients (patients 11 and 15) had recurrent microdeletions (16p11.2 and 22q11.22q11.23, respectively) identified by concurrent CMA. The 16p11.2 deletion, which includes the *PRRT2* gene, was also detected using ES coverage data from this patient.

###### Molecular Findings

  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Patient No.                                    Genomic Coordinates                Gene                                                Transcript       cDNA                       Protein Effect            Zygosity       Classification           Inheritance   Parental Origin           Diagnosis by
  ---------------------------------------------- ---------------------------------- --------------------------------------------------- ---------------- -------------------------- ------------------------- -------------- ------------------------ ------------- ------------------------- ------------------
  1                                              Chr1:160106162                     *ATP1A2*                                            NM_000702.3      c.2563 + 2T\>C                                       Het            Likely pathogenic        AD            Maternal                  Panel

  2                                              ChrX:53280248                      *IQSEC2*                                            NM_001111125.2   c.1510C\>T                 p.Gln504\*                Hem            Likely pathogenic        XLD           Unknown                   Panel

  3                                              ChrX:53279758-53279776             *IQSEC2*                                            NM_001111125.2   c.1983_1999del             p.Leu662fs                Het            Likely pathogenic        XLD           Unknown                   Panel

  4                                              Chr20:62038729                     *KCNQ2*                                             NM_172107.2      c.1888-1G\>A                                         Het            Likely pathogenic        AD            Unknown                   Panel

  5                                              ChrX:99662890                      *PCDH19*                                            NM_001184880.1   c.706C\>T                  p.Pro236Ser               Het            Likely pathogenic        XL            Unknown                   Panel

  6                                              Chr22:32098112-32270694            *PRR14L, DEPDC5*                                                     22q12.2 - q12.3 deletion                             Het            Likely pathogenic        AD            Unknown                   Panel

  7                                              Chr16:29824948-29824950            *PRRT2*                                             NM_001256442.1   c.577delG                  p.Glu193Lysfs\*36         Het            Pathogenic               AD            Unknown                   Panel

  8                                              Chr2:166850723-166850726           *SCN1A*                                             NM_001165963.1   c.4783_4784delCT           p.Leu1595fs               Het            Pathogenic               AD            Unknown                   Panel

  9                                              Chr2:166905395                     *SCN1A*                                             NM_001202435.1   c.1028 + 1G\>T                                       Het            Pathogenic               AD            Unknown                   Panel

  10                                             Chr2:166848438                     *SCN1A*                                             NM_001165963.1   c.5347G\>A                 p.Ala1783Thr              Het            Pathogenic               AD            Unknown                   Panel

  11                                             Chr16:29595483-30198151            *PPRT2*[^a^](#zoi190099t2n1){ref-type="table-fn"}                    16p11.2 deletion                                     Het            Pathogenic               AD            Unknown                   Panel

  12                                             Chr16:29652999-30194001            *PPRT2*[^b^](#zoi190099t2n2){ref-type="table-fn"}                    16p11.2 deletion                                     Het            Pathogenic               AD            Unknown                   Panel

  13                                             Chr9:130430431dup                  *STXBP1*                                            NM_003165.3      c.867dup                   p.Ala290Serfs\*24         Het            Pathogenic               AD            Unknown                   Panel

  14                                             Chr9:130430439                     *STXBP1*                                            NM_003165.3      c.875G\>A                  p.Arg292His               Het            Pathogenic               AD            Unknown                   Panel

  15[^c^](#zoi190099t2n3){ref-type="table-fn"}   Chr11:6638271; Chr11:6638385       *TPP1*                                              NM_000391.3      c.622C\>T;\                p.Arg208\*; p.?           Compound het   Pathogenic; pathogenic   AR            Both                      Panel
                                                                                                                                                         c.509-1G\>C                                                                                                                          

  16[^c^](#zoi190099t2n3){ref-type="table-fn"}   Chr9:138651532                     *KCNT1*                                             NM_020822.2      c.862G\>A                  p.Gly288Ser               Het            Pathogenic               AD            De novo, recurrent        Panel

  17                                             Chr19:42482319                     *ATP1A3*                                            NM_001256214.1   c.1829G\>A                 p.Arg610His               Het            Likely pathogenic        AD            Likely de novo            Parental testing

  18                                             Chr19:13372340                     *CACNA1A*                                           NM_023035.2      c.4186G\>A                 p.Val1396Met              Het            Likely pathogenic        AD            Likely de novo            Parental testing

  19                                             Chr5:161309591                     *GABRA1*                                            NM_000806.5      c.587A\>G                  p.Tyr196Cys               Het            Likely pathogenic        AD            Likely de novo            Parental testing

  20                                             Chr2:166848464                     *SCN1A*                                             NM_001165963.1   c.5321T\>C                 p.Phe1774Ser              Het, mosaic    Likely pathogenic        AD            De novo                   Parental testing

  21                                             Chr2:166231468                     *SCN2A*                                             NM_001040142.1   c.4246C\>T                 p.Leu1416Phe              Het            Likely pathogenic        AD            likely de novo            Parental testing

  22                                             Chr12:52200543                     *SCN8A*                                             NM_014191.3      c.5273T\>C                 p.Val1758Ala              Het            Likely pathogenic        AD            De novo                   Parental testing

  23                                             Chr15:25584341                     *UBE3A*                                             NM_000462.3      c.2550_2570dup             p.Glu851_Lys857dup        Het            Likely pathogenic        Imprinted     Likely de novo, unknown   Parental testing

  24                                             Chr5:92921095                      *NR2F1*                                             M_005654.5       c.366C\>G                  p.Cys122Trp               Het            Likely pathogenic        AD            De novo                   ES trio

  25                                             Chr18:42531889                     *SETBP1*                                            NM_015559.2      c.2584G\>A                 p.Glu862Lys               Het            Pathogenic               AD            De novo                   ES trio

  26                                             ChrX:53440181                      *SMC1A*                                             NM_006306.3      c.615 + 1G\>C                                        Het, mosaic    Pathogenic               XLD           De novo                   ES trio

  27[^d^](#zoi190099t2n4){ref-type="table-fn"}   Chr1:40319721-40319723; 40319730   *TRIT1*                                             NM_017646.5      c.334delC; c.326T\>C;      p.Arg112fs; p.Ile109Thr   Compound het   VUS; VUS                 AR            Both                      ES trio

  **Reanalysis Findings**                                                                                                                                                                                                                                                                     

  28                                             Chr22:40036960                     *CACNA1I*                                           NM_021096.3      c.829A\>G                  p.Ile277Val               Het            VUS                      AD            Unknown                   NA

  29                                             Chr2:149267668                     *MBD5*                                              NM_018328.4      c.4377T\>A                 p.His1459Gln              Het            VUS                      AD            Unknown                   NA

  30                                             Chr2:166020387                     *SCN3A*                                             NM_001081677.1   c.619G\>C                  p.Val207Leu               Het            VUS                      AD            Unknown                   NA

  31                                             Chr2:166025265                     *SCN3A*                                             NM_006922.3      c.454G\>A                  p.Asp152Asn               Het            VUS                      AD            Unknown                   NA

  32                                             Chr6:118015256                     *NUS1*                                              NM_138459.4      c.604A\>G                  p.Arg202Gly               Het            VUS                      AD            Unknown                   NA

  33                                             Chr3:132394747                     *UBA5*                                              NM_024818.4      c.1111G\>A                 p.Ala371Thr               Het            Pathogenic               AR            Unknown                   NA
  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Abbreviations: AD, autosomal dominant; AR, autosomal recessive; ES, exome sequencing; Hem, hemizygous; Het, heterozygous; NA, not applicable; VUS, variant of unknown significance; XL, X-linked; XLD, X-linked dominant.

Full list of genes in the microdeletion: *SEZ6L2*, *INO80E*, *SMG1P2*, *MIR3680-1*, *MIR3680-2*, *SPN*, *QPRT*, *C16orf54*,*ZG16*, *KIF22*, *MAZ*, *PRRT2*, *PAGR1*, *MVP*, *CDIPT*, *CDIPT-AS1*, *ASPHD1*, *KCTD13*, *TMEM219*, *TAOK2*, *HIRIP3*, *DOC2A*, *C16orf92*, *FAM57B*, *ALDOA*, *PPP4C*, T*BX6*, *YPEL3*, *LOC101928595*, *GDPD3*, *MAPK3*, *CORO1A*.

Microdeletion includes genes listed from *SPN* through *MAPK3* in footnote a.

Findings noted in medically actionable genes.

The report was marked as likely diagnostic owing to lack of definitive variant classification evidence and somewhat limited clinical validity of the gene.

Targeted Epilepsy Panel Findings {#H2-8-ZOI190099}
--------------------------------

Sixteen of the 151 patients (10.6%; 95% CI, 6%-16%) had diagnostic panel testing findings and therefore required no further testing ([Figure 2](#zoi190099f2){ref-type="fig"}A and [Table 2](#zoi190099t2){ref-type="table"}). Recurrent findings included *SCN1A* (n = 3), *STXBP1* (n = 2), *IQSEC2* (n = 2), and chromosome 16p11.2 deletion syndrome (n = 2) ([Table 2](#zoi190099t2){ref-type="table"}). Because the latter deletion includes the *PRRT2* gene, a total of 3 cases were diagnostic owing to findings involving this gene (2 deletions and 1 frameshift). Other diagnostic findings were in *ATP1A2*, *KCNQ2*, *KCNT1*, *PCDH19*, and *TPP1* genes. Of the 16 diagnostic results, 3 (18.8%) (2 in *PPRT2* and 1 in *DEPDC5*) had pathogenic CNVs detected using ES read-depth analysis and subsequently confirmed by orthogonal methods (concurrent diagnosis using CMA in patient 11). The exome-based CNV algorithm implemented added 2.0% (3 of 151) to the overall diagnostic yield.

![Diagnostic Outcomes\
A, Diagnostic outcome for different testing modules: proband-only panel, parental follow-up, exome sequencing (ES) trio reflex analysis, and overall. B, Diagnostic outcome by age at onset. C, Diagnostic reclassification by successive genetic testing. Numbers in circles indicate numbers of patients being retested.\
^a^Parental testing indicated for 28 of 64 patients (43.8%).\
^b^One patient was tested by both parental and ES trio follow-up and was also rendered negative.\
^c^Parental testing revealed the apparent de novo nature of the variants.\
^d^In genes not included in the panel.](jamanetwopen-2-e192129-g002){#zoi190099f2}

Twenty-three patients (15.2%) had likely diagnostic findings for which parental testing was necessary to establish a definitive diagnosis ([Figure 2](#zoi190099f2){ref-type="fig"}A), that is, to determine whether the variants were de novo or establish phase (*cis* or *trans*) in the case of recessive genes. Testing in 64 patients (42.4%) yielded inconclusive findings. Of those, parental testing was indicated for 28 patients (43.8%), but not for the remaining 36 patients (56.3%), owing to limited variant evidence or the presence of a single heterozygous pathogenic variant in recessive genes. Forty-eight patients (31.8%) had no reportable findings (negative).

Value of Follow-up Testing {#H2-9-ZOI190099}
--------------------------

Follow-up testing, consisting of parental testing (n = 15) or reflex trio exome analysis (n = 12), was performed for 26 of 135 patients (19.3%), with panel findings that were likely diagnostic in 6 patients (23.1%), inconclusive in 15 patients (57.8%), and negative in 5 patients (19.2%). One patient with panel-inconclusive findings underwent both parental follow-up and exome reflex. Although performed on a limited number of cases, parental and reflex exome testing found a causal variant in 11 of 26 studied cases (42.3%; 95% CI, 23%-62%), increasing the overall diagnostic yield by 7.3% (from 10.6% to 17.9%). Parental testing established 7 diagnosis (in *ATP1A3*, *CACNA1A*, *GABRA1*, *SCN1A*, *SCN2A*, *SCN8A*, and *UBE3A* genes), raising diagnostic yield by 4.7% to overall diagnostic yield of 15.3% (23 of 151; 95% CI, 9%-21%). Reflex exome analysis established 4 diagnosis (in *NR2F1*, *SETBP1*, *SMC1A*, and *TRIT1* genes), raising the diagnostic yield by 2.7% to overall diagnostic yield of 17.9% (27 of 151; 95% CI, 12%-24%).

Although parental testing was recommended for 23 likely diagnostic and 28 inconclusive probands, parental samples were received for only 6 likely diagnostic (26.1%) and 9 inconclusive (32.1%) probands. The recovery of samples for parental follow-up was only 29.4% (15 of 51). Diagnosis was established in 7 of 15 probands (46.7%; 95% CI, 21%-72%), of whom 4 had likely diagnostic and 3 had inconclusive panel findings ([Figure 2](#zoi190099f2){ref-type="fig"}C). Furthermore, inconclusive findings for 1 patient were upgraded to likely diagnostic, while negative results followed for 4 patients with panel-inconclusive findings. Altogether, parental testing decreased the inconclusive patient reports by 73% owing to reclassification of 11 (7 to diagnostic and 4 to negative reports).

Trio exome reflex testing was ordered for 7 patients with panel-inconclusive findings, 1 of whom had parental follow-up with negative outcome, and 5 patients with panel-negative results. This testing yielded a molecular diagnosis in 4 of 12 patients (33.3%; 95% CI, 6%-61%), of whom 2 had inconclusive panel findings and 2 had negative panel findings. The patient with panel-inconclusive findings followed by parental-negative results retained a negative result after ES trio. In addition, 1 patient with panel-inconclusive findings received a likely diagnostic result owing to the identification of de novo variants in 2 genes with limited clinical validity. Exome analysis rendered inconclusive findings for 2 patients with panel-negative results ([Figure 2](#zoi190099f2){ref-type="fig"}C).

We expect additional diagnostic findings as more nondiagnostic cases undergo follow-up testing. Although only 26.1% of patients with likely diagnostic panel findings underwent parental testing, 4 of them (66.7%) received diagnostic results.

Diagnostic Yield Stratification {#H2-10-ZOI190099}
-------------------------------

We investigated whether diagnostic yield varied by patient-specific attributes, namely, age at seizure onset, neurodevelopmental phenotype, seizure type, presence of magnetic resonance imaging findings, and family history ([Table 1](#zoi190099t1){ref-type="table"}). The most striking stratification was observed with respect to age at seizure onset. The diagnostic yield was highest in infants (aged 1-12 months) (17 of 44 \[38.6%; 95% CI, 24%-53%\]) followed by toddlers (aged 12-36 months) (8 of 50 \[16.0%; 95% CI, 6%-26%\]), contributing 11% and 5%, respectively, to the overall diagnostic yield in the cohort ([Table 1](#zoi190099t1){ref-type="table"} and [Figure 2](#zoi190099f2){ref-type="fig"}B). There was only 1 diagnostic outcome (by exome trio reflex) in the neonates (aged 0-1 month) (1 of 8 \[12.5%\]), and 1 diagnosis in probands with seizure onset in late childhood (aged 6-11 years) (1 of 19 \[5.3%\]). No diagnoses were established in children aged 3 to 5 years (n = 24) or patients aged 12 to 18 years) ([Table 1](#zoi190099t1){ref-type="table"}).

Exome Reanalysis {#H2-11-ZOI190099}
----------------

The exome-based approach enabled us to reanalyze patients with negative and inconclusive results (n = 124) by opening variant analysis to genes that were associated with epilepsy after the test launch in 2016. Thirteen new genes (*CACNA1E*, *CACNA1I*, *CLCN4*, *GABBR2*, *KCNMA1*, *KCNQ5*, *MBD5*, *NUS1*, *SCN3A*, *SLC25A42*, *SLC2A1*, *SNAP25*, and *UBA5*) were included in this reanalysis. Almost all exons in those genes had adequate sequence coverage.^[@zoi190099r15]^ Bioinformatics analysis identified 14 rare variants in these genes; however, on manual curation, only 6 variants in 6 patients were considered potentially significant ([Table 2](#zoi190099t2){ref-type="table"}).

One heterozygous pathogenic variant was identified in *UBA5*, a gene with an autosomal recessive inheritance pattern, but a second sequence variant or CNV was not identified, making the result inconclusive. However, the presence of clinically significant noncoding variants undetectable by this test cannot be excluded.

In 5 other patients, heterozygous variants were identified in 4 autosomal dominant genes. The variants were rare or absent from the general population and affected highly conserved amino acid residues and/or functional domains. However, additional functional and/or segregation data are needed to establish the clinical significance of the variants. As more variant information becomes available for those newly discovered genes, we anticipate that some, if not all, of those variants will play significant roles in the patients' seizures.

Discussion {#H1-4-ZOI190099}
==========

We have possibly validated and clinically implemented what may be a useful and flexible exome-based approach for genomic diagnostic testing of pediatric epilepsy. The overall diagnostic yield was 17.9% (27 of 151), which falls within the reported range by others (15%-28%).^[@zoi190099r21],[@zoi190099r22],[@zoi190099r23],[@zoi190099r24],[@zoi190099r25],[@zoi190099r26]^ Diagnostic yield was significantly higher (38.6%) for infants (aged 1-12 months; 17 of 44) compared with other age groups, supporting the clinical use of this diagnostic approach in pediatric epilepsy, especially for infancy-onset seizures.

The initial yield after analysis of the 100 panel genes was 10.6%. Follow-up parental testing and trio exome reflex testing on a limited number of patients with nondiagnostic results (n = 26) increased the overall yield by 7.3% for a final rate of 17.9%. This is a significant increase given the limited number of patients who underwent follow-up testing (26 of 135 \[19.3%\]). Seven of 15 patients (46.7%) who underwent parental follow-up testing and 4 of 12 patients (33.3%) who underwent exome reflex received diagnoses. Parental follow-up established diagnosis for 4 of 6 of the probands (66.7%) with initially likely diagnostic findings and 3 of 9 probands (33.3%) with initially inconclusive findings ([Figure 2](#zoi190099f2){ref-type="fig"}C). Determining the inheritance of the variants was necessary for establishing the molecular diagnoses in these probands. In addition, 4 of 15 (26.7%) of the patients received negative reports at parental follow-up, which decreased the inconclusive patient reports by 73% (7 diagnostic and 4 negative of 15 tested). Exome reflex uncovered diagnostic findings for 4 probands.

In addition to being a useful testing option, this exome-based approach may enable flexible update of panel gene content with minimal test validation to keep up with the continuous discovery of new epilepsy genes, and also allows periodic reanalysis on patients with nondiagnostic results. Reanalysis was performed on a limited number of genes (n = 13) for all patients who did not receive a molecular diagnosis within 1 year after initial testing (n = 124). Although this analysis uncovered promising findings in 6 patients, reanalysis on a larger number of genes and for an extended time (\>2 years after initial testing) might be more useful in identifying additional diagnoses.

The study findings are in agreement with recent reports that sequencing-based diagnostics is effective as first-tier testing in pediatric epilepsy.^[@zoi190099r21],[@zoi190099r27]^ Moreover, integration of copy number calling from ES makes the testing more comprehensive and increases cost-effectiveness by eliminating the necessity of CMA testing. The exome-based CNV algorithm implemented here identified pathogenic variants in 3 of 27 of the positive cases (11.1%) adding 2.0% (3 of 151) to the overall diagnostic yield.

Based on this study, we recommend that parental samples be obtained simultaneously with the proband's because parental samples are necessary for interpretation of identified variants. We recommend that proband-only exome-based rapid analysis of a preselected set of genes should be the first step, followed by parental testing of select inconclusive findings and then ES trio testing of the remaining patients with nondiagnostic results ([Figure 3](#zoi190099f3){ref-type="fig"}A).

![Current and Alternative Strategies for Genetic Testing in Childhood Epilepsy\
A, Current strategy: proband-only exome sequencing (ES) followed by parental testing of select patients with inconclusive results and reflex to ES trio testing of the remaining patients with nondiagnostic results. B, Alternative trio ES panel strategy: starts with ES trio (proband plus parents) panel analysis followed by immediate reflex to ES analysis for trios with nondiagnostic panel results. The percentage of cases at each testing stage is extrapolated to the full cohort using this study's data. Test costs are in reference to proband-only ES panel as the base cost (relative cost: proband-only ES panel: X; trio ES panel: 1.7X; ES trio testing: 2.5X; overall cohort cost: strategy B is less than 10% higher than strategy A).](jamanetwopen-2-e192129-g003){#zoi190099f3}

Alternatively, a strategy in which initial testing includes an ES panel on a family trio (parents and proband) could be considered ([Figure 3](#zoi190099f3){ref-type="fig"}B). This strategy would eliminate the need for follow-up parental testing and would increase the confidence for de novo findings by providing the certainty for a biological relationship, which would enable immediate reflex to whole-exome analysis and decrease the time to diagnosis. A disadvantage of this panel trio strategy, however, would be the unnecessary cost of parental ES for 11% of patients with diagnostic panel results. Extrapolating from parental follow-up data in [Figure 2](#zoi190099f2){ref-type="fig"}C, parental testing could reveal diagnosis in an additional 16% of the patients, and reflex to ES trio would be indicated for the remaining 73% of probands ([Figure 3](#zoi190099f3){ref-type="fig"}A). Based on these numbers, the cost of the 2 strategies is comparable, with the panel trio strategy adding less than 10% additional costs ([Figure 3](#zoi190099f3){ref-type="fig"}B). This is because the cost of testing is driven by analysis and interpretation costs rather than sequencing cost, with the former accounting for approximately 70% for proband-only ES and 60% for ES trio testing. Despite the increase in sequencing costs for 27% of the probands, the analysis/interpretation cost would be significantly reduced (owing to automated inheritance modeling), which would partially offset the increase in sequencing costs. In addition, this moderate increase in testing cost might be worthwhile given the health care benefits of the shortened time to diagnosis, which is not only associated with reduced overall cost of the patient\'s diagnostic workup, but would also be of significance for delivering timely, personalized treatments.

Limitations {#H2-12-ZOI190099}
-----------

The main limitations of this study include a relatively small sample size, possible selection bias of patients who received testing, and significant loss of samples to parental and ES reflex follow-up. Clinicians' decisions on which patients would benefit from this test could cause patient selection bias, which would lead to an overestimation of contribution of parental and ES follow-up testing in assessing overall diagnostic yield. The recovery of samples for parental follow-up was only 29.4% (15 of 51), which could be attributable to parental availability, as parental testing was free-of-charge. However, availability of insurance coverage may have contributed to the reduced numbers of reflex to ES trio analysis.

Conclusions {#H1-5-ZOI190099}
===========

Most epilepsy genetic testing is based on a proband-only 1-and-done strategy. This case series report suggests that both parental testing and reflex to ES are important for maximizing diagnostic yield. The study also supports the importance of regular reanalysis efforts to incorporate newly discovered epilepsy gene evaluation and demonstrates exome-based panels as a readily amenable option for this purpose.
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